A pharmaceutical composition of the present invention containing an extract of Lysimachia clethroides significantly protected dopaminergic neurons in the Parkinson's animal model, increased dopamine levels, and significantly inhibited microglial activation and neuroinflammation. Thus, the pharmaceutical composition significantly reduced ataxia, which is a symptom of Parkinson's disease. Further, the extract of Lysimachia clethroides significantly inhibited the increase in IL-6 expression in the Parkinson's animal model, which was proved to be a main action mechanism. Therefore, the pharmaceutical composition of the present invention can exhibit effects of treatment and prevention of Parkinson's disease by the extract of Lysimachia clethroides contained therein. [Reference numerals] (AA) Pharmacological effect of the extract of Lysimachia clethroides on the reduction of tyrosine hydroxylase expression (evaluated by immunohistochemical staining) in (A) Striatum and (B) Substantia nigra induced by MPTP in wild-type or IL-6 knockout [IL-6 (-/-)] mice. Veh=Vehicle. Each value means the mean 짹 SEM. ^*P <；0.05, ^**P <； 0.01 vs, corresponding Vehicle + Saline, ^*P <；0.05,^**P <； 0.01 vs Wild-type/ Vehicle + MPTP, ^&P <； 0.05 vs IL-6 (-/-)/ Vehicle + MPTP (one-way ANOVA. followed by Fisher's PLSD post hoc test)큰까치수영 추출물 (큰까치수영 추출물)을 함유하는 본 발명의 약제학적 조성물은 파킨슨의 동물모델에서 도파민성 신경세포를 유의하게 보호하고 도파민 수치를 증가시키며, 소교세포 활성화 및 신경염증반응을 유의하게 억제하였다. 따라서 파킨슨병의 증상인 운동실조도 유의하게 감소하였다. 또한, 큰까치수영 추출물은 파킨슨병의 동물모델에서 IL-6 발현의 증가를 유의하게 억제하였으며, 이것이 주요 작용기전임을 증명하였다. 따라서, 본 발명의 약제학적 조성물은 조성물에 포함된 큰까치수영 추출물에 의해 파킨슨병의 치료 및 예방 효과를 나타낼 수 있다.
